Skybiotech Healthcare Limited will hold its 43rd Annual General Meeting on Wednesday, September 30, 2026. The physical meeting is scheduled to begin at 11:00 am at the company’s registered office in Chh. Sambhaji Nagar (Aurangabad), Maharashtra.

The meeting agenda covers ordinary business items for the financial year ended March 31, 2026. Shareholders will consider and adopt both the Audited Standalone and Consolidated Financial Statements, along with the Board Report and Auditors’ Reports.

Key Agenda Items

The notice outlines specific resolutions for shareholder approval:

• Adoption of Financials: Approval of standalone and consolidated financial results for FY26.
• Director Re-appointment: Re-appointment of Mr. Prakashchandra Rathi, who retires by rotation and offers himself for re-election.
• Statutory Auditor Appointment: Appointment of M/s. SPD & Associates, Chartered Accountant (FRN: 139118W), as statutory auditors. They are proposed to hold office for five consecutive years, from the conclusion of this AGM until the conclusion of the 48th AGM in FY2031.

Voting and Logistics

The company has dispatched the AGM notice and Annual Report electronically to members who registered their email addresses with the Registrar and Transfer Agent or Depository Participants. The record date for determining voting eligibility is August 28, 2026.

Shareholders holding shares as on the cut-off date may cast their votes electronically through the National Securities Depository Limited (NSDL) platform. The e-voting module will be active from September 26, 2026, at 10:00 am until September 29, 2026, at 5:00 pm. Members who vote remotely will not be eligible to vote again via poll paper at the physical meeting.

SM Dhumal & Associates, Practicing Company Secretary, has been appointed as the scrutinizer to ensure a fair and transparent e-voting process. Results will be declared on or after the AGM and posted on the company’s website within two days.

Skybiotech Healthcare Limited reported a consolidated net loss of ₹111.68 lakh for the financial year ended March 31, 2026, narrowing from a loss of ₹236.89 lakh in the previous year. The company's board approved the audited financial results for the quarter and year ended March 31, 2026, at a meeting held on May 30, 2026. The statutory auditor, SPD & Associates, issued an unmodified opinion on the standalone and consolidated financial results.

Consolidated Financial Performance

For the year ended March 31, 2026, the company reported total income of ₹740.38 lakh, a slight decrease from ₹743.45 lakh in FY25. Total expenses for the period stood at ₹907.04 lakh, down from ₹986.00 lakh in the previous year. The profit before tax for the year was a loss of ₹166.66 lakh, compared to a loss of ₹242.55 lakh in FY25.

Standalone Results

On a standalone basis, the company reported a net loss of ₹6.03 lakh for FY26, compared to a net profit of ₹5.96 lakh in the previous year. Total income for the year stood at ₹6.69 lakh, significantly lower than the ₹18.12 lakh reported in FY25. Total expenses increased to ₹12.69 lakh from ₹10.53 lakh in the prior year.

The board also reviewed the limited review report for the quarter and took on record the audit report issued by the statutory auditors. The meeting was conducted in compliance with Regulation 30 of the SEBI (LODR) Regulations, 2015.